Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.

Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P; ACTG 709 Team..

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):1-8. doi: 10.1097/QAI.0b013e318224d0c7.

2.

Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.

Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C.

AIDS. 2005 Jan 3;19(1):25-33.

PMID:
15627030
3.

Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants.

Scott ZA, Chadwick EG, Gibson LL, Catalina MD, McManus MM, Yogev R, Palumbo P, Sullivan JL, Britto P, Gay H, Luzuriaga K; PACTG(Pediatric AIDS Clinical Trial Group) 345 Investigators..

J Immunol. 2001 Dec 15;167(12):7134-40.

5.
6.

Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals.

Trabattoni D, Piconi S, Biasin M, Rizzardini G, Migliorino M, Seminari E, Boasso A, Piacentini L, Villa ML, Maserati R, Clerici M.

AIDS. 2004 Apr 9;18(6):859-69.

PMID:
15060433
7.

A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.

Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, Jahed NC, Jacobson JM, Myers LS, Schmitz JL, Winters M, Tebas P; A5102 Study Team of the AIDS Clinical Trials Group..

J Acquir Immune Defic Syndr. 2006 Jun;42(2):140-8.

PMID:
16760795
8.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group..

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
9.

HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.

Papasavvas E, Kostman JR, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R, Jordan KA, Nixon DF, Grant R, Poulin JF, McCune JM, Mounzer K, Montaner LJ.

J Clin Immunol. 2006 Jan;26(1):40-54.

PMID:
16418802
10.

Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy.

Keane NM, Price P, Stone SF, John M, Murray RJ, French MA.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):1991-6.

PMID:
11153082
11.

Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.

Gamberg J, Barrett L, Bowmer I, Howley C, Grant M.

J Clin Immunol. 2004 Mar;24(2):115-24.

PMID:
15024178
12.

Interferon-gamma responses to Candida recover slowly or remain low in immunodeficient HIV patients responding to ART.

Burgess K, Price P, James IR, Stone SF, Keane NM, Lim AY, Warmington JR, French MA.

J Clin Immunol. 2006 Mar;26(2):160-7. Epub 2006 Mar 28.

PMID:
16568352
13.

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ.

J Infect Dis. 2000 Sep;182(3):766-75. Epub 2000 Aug 17.

PMID:
10950770
14.

Proliferative, IFNgamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection.

Alatrakchi N, Damond F, Matheron S, Beretta-Tempelhoff S, Campa P, Carcelain G, Brun-Vezinet F, Autran B; French HIV-2 study group..

AIDS. 2006 Jan 2;20(1):29-34.

PMID:
16327316
15.

Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, Rouzioux C, Taoufik Y, El Habib R, Beumont-Mauviel M, Aboulker JP, Lévy Y, Delfraissy JF; PRIMOVAC-ANRS 095 Study Group..

AIDS Res Hum Retroviruses. 2007 Sep;23(9):1105-13.

PMID:
17919105
16.

Phenotype and functional characteristics of HIV-specific cytotoxic CD8+ T cells in chronically infected patients: dual effects of highly active antiretroviral therapy.

Benito JM, López M, Lozano S, Martinez P, Kuroda M, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):255-66.

PMID:
14600569
17.

Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.

Zheng L, Taiwo B, Gandhi RT, Hunt PW, Collier AC, Flexner C, Bosch RJ.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):153-60. doi: 10.1097/QAI.0000000000000286.

18.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

19.

HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.

Rallón NI, Soriano V, Restrepo C, García-Samaniego J, Labarga P, López M, Peris A, González-Lahoz J, Benito JM.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):1-8.

PMID:
21786458
20.

Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment.

Huang S, Dunkley-Thompson J, Tang Y, Macklin EA, Steel-Duncan J, Singh-Minott I, Ryland EG, Smikle M, Walker BD, Christie CD, Feeney ME.

J Immunol. 2008 Dec 1;181(11):8103-11.

Supplemental Content

Support Center